Daratumumab monotherapy may be useful in patients with intermediate-risk or high-risk smouldering multiple myeloma (SMM) to delay their progression to MM. A phase 2 study of the monoclonal antibody in 123 patients from 47 sites worldwide said a primary end point of progressive disease (PD)/death rate less 0.346/ patient-year suggested activity against SMM. It found ...
Early intervention with daratumumab may head off myeloma
By Mardi Chapman
12 Feb 2020